FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2401994137> ?p ?o ?g. }

• W2401994137 endingPage "40251" @default.
• W2401994137 startingPage "40233" @default.
• W2401994137 abstract "// Kamila K. Kaminska 1 , Helene C. Bertrand 2, 4 , Hisashi Tajima 2 , William C. Stafford 3 , Qing Cheng 3 , Wan Chen 1 , Geoffrey Wells 2 , Elias S.J. Arner 3 , Eng-Hui Chew 1 1 Department of Pharmacy, Faculty of Science, National University of Singapore, S117543, Republic of Singapore 2 UCL School of Pharmacy, University College London, London WC1N 1AX, United Kingdom 3 Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77, Stockholm, Sweden 4 Current address: École Normale Supérieure, PSL Research University, Département de Chimie, Sorbonne Universités, UPMC Univ Paris 06, CNRS UMR 7203 LBM, 75005 Paris, France Correspondence to: Eng-Hui Chew, email: phaceh@nus.edu.sg Keywords: anticancer, indolin-2-one, supercinnamaldehyde, selenocysteine, thioredoxin reductase Received: October 28, 2015     Accepted: April 18, 2016     Published: May 24, 2016 ABSTRACT Several compounds bearing the indolinone chemical scaffold are known to possess anticancer properties. For example, the tyrosine kinase inhibitor sunitinib is an arylideneindolin-2-one compound. The chemical versatility associated with structural modifications of indolinone compounds underlies the potential to discover additional derivatives possessing anticancer properties. Previously synthesized 3-(2-oxoethylidene)indolin-2-one compounds, also known as supercinnamaldehyde (SCA) compounds in reference to the parent compound 1 [1-methyl-3(2-oxopropylidene)indolin-2-one], bear a nitrogen-linked α,β-unsaturated carbonyl (Michael acceptor) moiety. Here we found that analogs bearing N -substituents, in particular compound 4 and 5 carrying an N -butyl and N -benzyl substituent, respectively, were strongly cytotoxic towards human HCT 116 colorectal and MCF-7 breast carcinoma cells. These compounds also displayed strong thioredoxin reductase (TrxR) inhibitory activity that was likely attributed to the electrophilicity of the Michael acceptor moiety. Their selectivity towards cellular TrxR inhibition over related antioxidant enzymes glutathione reductase (GR), thioredoxin (Trx) and glutathione peroxidase (GPx) was mediated through targeting of the selenocysteine (Sec) residue in the highly accessible C-terminal active site of TrxR. TrxR inhibition mediated by indolin-2-one compounds led to cellular Trx oxidation, increased oxidative stress and activation of apoptosis signal-regulating kinase 1 (ASK1). These events also led to activation of p38 and JNK mitogen-activated protein kinase (MAPK) signaling pathways, and cell death with apoptotic features of PARP cleavage and caspase 3 activation. In conclusion, these results suggest that indolin-2-one-based compounds specifically targeting TrxR may serve as novel drug leads for anticancer therapy." @default.
• W2401994137 created "2016-06-24" @default.
• W2401994137 creator A5012576392 @default.
• W2401994137 creator A5035586555 @default.
• W2401994137 creator A5051690404 @default.
• W2401994137 creator A5059122082 @default.
• W2401994137 creator A5061352424 @default.
• W2401994137 creator A5068845562 @default.
• W2401994137 creator A5074081555 @default.
• W2401994137 creator A5075893388 @default.
• W2401994137 creator A5085491395 @default.
• W2401994137 date "2016-05-24" @default.
• W2401994137 modified "2023-10-10" @default.
• W2401994137 title "Indolin-2-one compounds targeting thioredoxin reductase as potential anticancer drug leads" @default.
• W2401994137 cites W121410703 @default.
• W2401994137 cites W1504064499 @default.
• W2401994137 cites W1802175835 @default.
• W2401994137 cites W1969268163 @default.
• W2401994137 cites W1971886251 @default.
• W2401994137 cites W1972779889 @default.
• W2401994137 cites W1978690847 @default.
• W2401994137 cites W1983209594 @default.
• W2401994137 cites W1983397667 @default.
• W2401994137 cites W1987250101 @default.
• W2401994137 cites W1988381334 @default.
• W2401994137 cites W1991303607 @default.
• W2401994137 cites W1993058298 @default.
• W2401994137 cites W1996311090 @default.
• W2401994137 cites W1999721954 @default.
• W2401994137 cites W2000901659 @default.
• W2401994137 cites W2001338101 @default.
• W2401994137 cites W2002462958 @default.
• W2401994137 cites W2013040616 @default.
• W2401994137 cites W2015317041 @default.
• W2401994137 cites W2016051676 @default.
• W2401994137 cites W2018729412 @default.
• W2401994137 cites W2020821477 @default.
• W2401994137 cites W2028556682 @default.
• W2401994137 cites W2030661039 @default.
• W2401994137 cites W2034224169 @default.
• W2401994137 cites W2034580062 @default.
• W2401994137 cites W2034902084 @default.
• W2401994137 cites W2046987575 @default.
• W2401994137 cites W2050083026 @default.
• W2401994137 cites W2073880421 @default.
• W2401994137 cites W2077845630 @default.
• W2401994137 cites W2078620397 @default.
• W2401994137 cites W2082467091 @default.
• W2401994137 cites W2096245406 @default.
• W2401994137 cites W2096492418 @default.
• W2401994137 cites W2099877688 @default.
• W2401994137 cites W2109557300 @default.
• W2401994137 cites W2129778797 @default.
• W2401994137 cites W2129829963 @default.
• W2401994137 cites W2139511378 @default.
• W2401994137 cites W2149585271 @default.
• W2401994137 cites W2149659371 @default.
• W2401994137 cites W2152203826 @default.
• W2401994137 cites W2153831810 @default.
• W2401994137 cites W2156408558 @default.
• W2401994137 cites W2157486480 @default.
• W2401994137 cites W2159278761 @default.
• W2401994137 cites W2159638148 @default.
• W2401994137 cites W2164166653 @default.
• W2401994137 cites W2165105321 @default.
• W2401994137 cites W2165846038 @default.
• W2401994137 cites W2165980159 @default.
• W2401994137 cites W2166017917 @default.
• W2401994137 cites W2170101247 @default.
• W2401994137 cites W2171258641 @default.
• W2401994137 cites W2330896126 @default.
• W2401994137 cites W2415763315 @default.
• W2401994137 cites W71837605 @default.
• W2401994137 doi "https://doi.org/10.18632/oncotarget.9579" @default.
• W2401994137 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5130005" @default.
• W2401994137 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27244886" @default.
• W2401994137 hasPublicationYear "2016" @default.
• W2401994137 type Work @default.
• W2401994137 sameAs 2401994137 @default.
• W2401994137 citedByCount "21" @default.
• W2401994137 countsByYear W24019941372017 @default.
• W2401994137 countsByYear W24019941372018 @default.
• W2401994137 countsByYear W24019941372019 @default.
• W2401994137 countsByYear W24019941372020 @default.
• W2401994137 countsByYear W24019941372021 @default.
• W2401994137 countsByYear W24019941372022 @default.
• W2401994137 crossrefType "journal-article" @default.
• W2401994137 hasAuthorship W2401994137A5012576392 @default.
• W2401994137 hasAuthorship W2401994137A5035586555 @default.
• W2401994137 hasAuthorship W2401994137A5051690404 @default.
• W2401994137 hasAuthorship W2401994137A5059122082 @default.
• W2401994137 hasAuthorship W2401994137A5061352424 @default.
• W2401994137 hasAuthorship W2401994137A5068845562 @default.
• W2401994137 hasAuthorship W2401994137A5074081555 @default.
• W2401994137 hasAuthorship W2401994137A5075893388 @default.
• W2401994137 hasAuthorship W2401994137A5085491395 @default.
• W2401994137 hasBestOaLocation W24019941371 @default.
• W2401994137 hasConcept C181199279 @default.

• next